Call for Abstracts

Late Breaking Clinical Trial

Please download and fill in the Abstract Submission Form and send it to the Secretariat by e-mail ( cvit2019@c-linkage.co.jp ).
Submission deadline: July 1 (JPT)

Abstract Submission Form

Submission Period

March 20 (Wed.) -	~~April 25 (Thur.), 2019 →~~
	~~May 16 (Thur.), 2019 →~~	~~May 23 (Thur.), 2019~~
		Abstract Submission was closed.

How to Submit Abstracts

All submissions must be made online via this website.

Application Qualification

If author and co-authors for this registration belong to overseas affiliations, they are not required to be a member of the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT). However, if the author/co-author belongs to an institution in Japan, membership registration to CVIT by the meeting dates is required.

Presentation Type

01	Contributed Paper for Oral
02	Contributed Paper for Poster
03	Symposium (SY) / Panel Discussion (PD)
04	Others

Session

* If you select 03. Symposium/Panel Discussion for Presentation Type, you will be requested to select one of the sessions below. (Required)

SY01	Consider AUC criteria in Japan Objective In Japan, for PCI, the importance of ischemic diagnosis recently increased. Accordingly, the clinical significance of PCI's appropriate use criteria are investigated again.
SY02	Imaging in EVT Objective Conventionally, imaging in EVT mainly consists of angiography. The importance of intravascular imaging was recently indicated. In this study, the clinical significance of imaging for EVT is investigated.
SY03	Endoluminal bypass in the peripheral artery Objective Last year, in EVT, VIABAHN became usable. In this study, endoluminal bypass using this device is investigated for its efficacy and safety.
SY04	Complication and bailout of TAVI (Case-based) Objective TAVI may cause critical complications. If bailout management is possible, it can greatly influence the TAVI treatment results. In this study, the complications and bailout management are studied.
SY05	Evolution of CTO-PCI Objective In recent PCI, the successful treatment rate for CTO is not 100%. In this study, efforts to improve the treatment results are investigated.
SY06	EVT for highly calcified lesions Objective Highly calcified lesions in EVT area greatly influences EVT success and failure. In this study, treatment of the calcified lesions is investigated.
SY07	Complication and bailout CTO-PCI Objective CTO-PCI is usually conducted for stable angina pectoris. However, when complications occur, the condition may become severe in many cases. In this study, the bailout management is investigated.
SY08	Stentless PCI: DCA/DCB/ELCA etc. Objective Since BRS appeared, stentless PCI has gained attention. In this study, treatment results of DCA/DCB/ELCA etc. playing a central role in PCI is investigated.
SY09	Complication and bailout in EVT Objective Even in EVT, once a complication occurs, lapse into shock is not rare. In this study, bailout management is studied.
SY10	Nightmare of complex PCI/complication and bailout Objective Even in facilities with rich PCI volume or facilities with relatively less volume, critical complications are not rare. In this study, bailout management is studied.
SY11	DCB vs stent? SFA treatment Objective The best option for SFA treatment remains unknown. In this study, treatment results in DCB vs stents and future directions are investigated.
SY12	CTA/HeartFlow Objective Although the importance of FFR was recently established, FFR can be calculated with high reliability in non-invasive CTI. In this study, focusing on the functional evaluation based on coronary arterial CT and its usefulness and pitfalls are studied.
SY13	CAS/CEA vs PCI/CABG - Which is first？ Objective The combination of coronary arterial disease and cervical arterial stenosis is often seen. In this case, the matter which priority is given to the former (PCI/CABG) or the latter (CAS/CEA) is a problem. In this symposium, treatment strategies is discussed with the experts.
SY14	Coronary imaging and physiology Objective It has been approximately 1 year since the items of functional evaluation for PCI was added to the calculation of reimbursement of medical fees. How does the ischemic evaluation in Japan change? In this session, knowledge of the coronary circulation that can be understood from imaging and physiology is reviewed. Unknown fields of coronary circulation that should be clarified by interventionists and future directions for study are elucidated.
SY15	Discriminated use of DES and DAPT Objective Six types of DES are currently usable in Japan. There are various opinions about DAPT types and duration in patients at high risk of bleeding. In this study, the matter is investigated.
SY16	Does the angiography-based FFR simulation change the work flow in the cath lab? Objective To gather evidence of non-pressure-wire-derived physiological assessment in terms of decision-making of treatment strategy in patients with multi-vessel disease (e.g. QFR, FFR-CT).
SY17	Vulnerable patient: an endless debate Objective If a lesion is unstable and will become responsible for future events, the high-risk lesion may become an indication for PCI. To determine the indication for PCI based on lesion instability but not ischemia, the possibility and usefulness are discussed with future perspectives.
SY18	New rule of catheter intervention in medical care of cerebral apoplexy Objective PFO closure surgery and closure surgery of the left atrial appendage for preventing recurrent cryptogenic cerebral infarction will be introduced as an intervention in Japan. The field is handled jointly by physicians in the cardiovascular medicine and physicians specializing in cerebral apoplexy. From their individual standpoints, its usefulness, cautions in its introduction, and future perspectives are studied.
SY19	Treatment strategies for SFA complex lesions in drug elution device era Objective Regarding interventions for shallow femoral arterial lesions, in addition to conventional balloon and bare-metal stents, newly introduced methods include percutaneous graft in 2017, drug-eluting balloon in 2018, and new drug-eluting stent in 2019. As such, innovative treatment methods are anticipated. Conventionally, surgical bypass has been made the first option for TASCIIC/D lesions. With the introduction of new devices for the lesion, how the treatment becomes innovative and future perspectives of each device are discussed.
SY20	Clinical standard for ischemic diagnosis is investigated. Objective How various modalities are used individually in routine clinical practice and within health insurance treatment are studied. The features and advantages/disadvantages of each modality are clarified. In the overall discussion, which modality is useful for certain case groups is discussed as the first step to create its standard in Japan.
SY21	Cardiovascular disease in women Objective Sex-based differences in cardiovascular disease has been a worldwide topic. Potentially different manifestations and outcomes of cardiovascular diseases in women will be discussed.
SY22	Treatment strategies for coronary arterial calcified lesions Objective Strategies for the initial success of PCI and coronary arterial calcified lesions disturbing chronic outcomes are discussed and limitations with device selection and complications are investigated.
SY23	Actual and current situation of AMI in Japan - The importance of registry data is considered Objective In-hospital mortality in patients with AMI decreased to below 10% but still feature many problems in hospital care and follow-up. It is important to know the current status of ACS in Japan, and we will find regional differences in the emergency medical care system.
SY24	Distal radial approach: a new standard of coronary access? Objective Recently, PCI by the distal radial arterial approach has become widespread. The approach's merits/demerits, results, and tips and tricks are studied.
SY25	OCT/OFDI for optimal PCI Objective It was recently clarified that PCI guided by OCT/OFD is not inferior to IVUS guide in terms of clinical results. The merits and demerits of OCT/OFDI-guided PCI are clarified to make them more widely used in routine clinical practice.
SY26	Treatment strategies of instable lesions by intravascular imaging guidance Objective The intravascular imaging diagnoses enables the classification of unstable plaques such as plaque rupture, erosion, and calcified nodes. Based on actual cases and experiences, diagnostic/treatment strategies are studied.
SY27	SHD heart team session Objective In SHD intervention, the total heart team is required for preoperative assessment, techniques, and postoperative management. In this session, its indication in each actual case and strategies in each facility are discussed and the actual situation of SHD interventions in Japan is discussed. (Invitation only for facility/team)
SY28	3D-OCT Objective OCT/OFD, which use the high resolution and flame rate, enables a detailed evaluation of the coronary arteries and stents by 3D reconstruction. In this study, the clinical usefulness of 3D-OCT/OFDI is discussed and its future possibilities are considered.
SY29	Multi-disciplinary approach to CLI Objective In critical limb ischemia (CLI), only EVT often cannot treat the extremities. In this session, the possibility of treating the extremities by multiple approaches such as early detection, effective vascular reconstruction, drug treatment, and foot care are studied.
SY30	Approach to CKD patients Objective It is well known that CKD influences the prognosis of patients with coronary arterial disease. It is extremely important to consider how the perioperative period of PCI in patients with complicated CKD is managed. In this session, strategies for improving prognosis are discussed.
SY31	Hemodynamic assist device: when and how to use? Objective In addition to IABP and PCPS, IMPELLA recently became usable as a percutaneous circulation assist device. In this study, the timing of introducing IMPELLA and its use combined with PCPS (ECPELLA) are studied.
SY32	MitraClip Taped Case Objective There have been significant changes in MR therapy at MitraClip clinical sites. These cases will be reviewed in this session.
SY33	Complication & Bailout of TAVR (Lecture) Objective Although the effectiveness of TAVI has been recognized, it is vital to bailout from situations once complications have occurred. This situation will be discussed in this session.
SY34	Endothelial Shear Stress (ESS) and Plaque Progression Objective In recent years, it has become clear that Endothelial Shear Stress (ESS) plays a significant role in the progression of arteriosclerosis. The relationship between ESS and plaque progressions will be examined in this session.
SY35	ACS Pathology and Imaging Objective Even as the mechanisms for ACS have been established pathologically, mechanisms in vivo are being clarified with recent developments in various imaging techniques. This session will feature in-depth discussions on these points.
SY36	Importance of Coronary Artery Disfunctions in the PCI Era Objective In recent years, a spotlight has been turned on coronary artery dysfunctions following the placement of stents for coronary arteries. This issue will be discussed in-depth in this session.
SY37	Left Main PCI: Imaging Physiology, technique and data Objective In this session, the Left Main PCI will be examined based on data, such as imaging physiology, optimal techniques and excel research.
SY38	Significance of ASA with the DAPT 2019 Update Objective In recent years, the significance of aspirin in DAPT has started to be reevaluated. This point will be discussed in this session.
SY39	MVD disease / SYNTAX Objective A significant amount of time has passed since a new chapter has been opened for MVD Disease treatments using SYNTAX studies. The current status of MVD disease will be presented in this session.

Category for Contributed Papers

01	ACS	28	ICD/CRT/CRTD
02	Antiplatelet Therapy	29	ISR
03	Assist Device	30	IVUS/OCT/Angioscopy
04	Bifurcated Lesion	31	Kawasaki Disease
05	BMS	32	Laser Angioplasty
06	BRS	33	LMT
07	CABG/CABG vs. PCI	34	Mitral Valve Treatment
08	CAS	35	Multivessel Disease
09	Catheter Ablation	36	Pathology
10	CKD/HD	37	Peripheral Artery Disease (PAD)
11	CLI	38	POBA/Cutting Balloon/Scoring Device
12	Complications	39	Prognosis
13	Congenital Heart Disease	40	PTSMA
14	CT/MRI/Scintigraphy	41	Pulmonary Embolism/DVT
15	CTEPH/BPA	42	Regenerative Therapy
16	CTO	43	Renal Denervation
17	DES	44	Restenosis
18	Diabets	45	Rotablator/DCA
19	Distal Protection Devices/Thrombectomy	46	Secondary Prevention/OMT
20	DVT/Venous Disease	47	Small Vessel Disease/Diffuse Lesion
21	Dyslipidemia/HT/Smoking/Other Risk Factors	48	Stent Graft
22	Emergency Care	49	Stent Thrombosis
23	Endovascular Intervention	50	TAVI/Valvuloplasty
24	Epidemiology	51	Thrombolysis
25	Financial Cost	52	TRI
26	Flow Wire/Pressure Wire/FFR CT	53	PH/BPA
27	Heart Failure	54	Others

Length of Abstract

Title of Abstract: Up to 20 words
Body of Abstract: Up to 220 words without a figure or a table (130 words with a figure or a table)
Please note you cannot complete the submission if the number of words goes beyond the limits.

Abstract Submission

New Submission

ciphertext-based
plaintext-based

View / Edit / Delete Submitted Abstract

ciphertext-based
plaintext-based

For security reasons, we recommend you not to use plaintext-based web communications for your abstract submission.

* This abstract submission system works only on the following browsers: Internet Explorer, Firefox, Google Chrome and Safari (ver. 2.0.3 (471.9.2) or later). Please do not use other browsers for abstract submission.

How We Handle Personal Information

The CVIT2019 entrusts the collecting, storing, and handling of the personal information provided to us, to University hospital Medical Information Network (UMIN) Center.

The personal information that you provide through the online submission system, will be used for the following purposes only:

1) to answer your inquiries regarding the meeting.
2) to send you the notification of review results.
3) to post your names, affiliations, presentation titles and abstracts on the official website and publish the program book / meeting APP.

Contact for CVIT Membership

The Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT)
TEL: +81-3-6280-4126 FAX: +81-3-6280-4127
E-mail: info@cvit.jp
CVIT website (Japanese only): http://www.cvit.jp/

Inquires

Congress Secretariat
c/o Convention Linkage, Inc.
Asahiseimei Bldg., 3-32-20, Sakae, Naka-ku, Nagoya, 460-0008 Japan
TEL：+81-52-262-5070　FAX：+81-52-262-5084
cvit2019@c-linkage.co.jp